Skip to main content

CASE REPORT article

Front. Pharmacol.
Sec. Pharmacology of Anti-Cancer Drugs
Volume 15 - 2024 | doi: 10.3389/fphar.2024.1448291

Case report: Efficacy of anlotinib and sintilimab in treating lung adenocarcinoma with RET fusion and PD-L1 expression

Provisionally accepted
Hejing Bao Hejing Bao 1,2*Jiani Zhang Jiani Zhang 3Yuhuan Wang Yuhuan Wang 3Zhiting Chen Zhiting Chen 3Xi Luo Xi Luo 1Ting Li Ting Li 1Haoran Su Haoran Su 1Hehong Bao Hehong Bao 2Xiaolong Cao Xiaolong Cao 1Liping Lin Liping Lin 1
  • 1 Department of Oncology, Guangzhou Medical University, Guangzhou, Guangdong Province, China
  • 2 Chongqing University, Chongqing, China
  • 3 Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong Province, China

The final, formatted version of the article will be published soon.

    We report a case of an advanced non-small cell lung cancer (NSCLC) patient with brain metastasis, RET fusion, and high expression of programmed death ligand 1 (PD-L1) at initial treatment. After receiving radiotherapy for the brain metastasis, the patient started with anlotinib and added immunotherapy with sintilimab. The patient had a good response to anlotinib and sintilimab treatment, tolerated the adverse reactions, and had a progression-free survival(PFS) of over 17 months. To the best of our knowledge, this is the first clinical case report in the literature describing the benefit of anlotinib and sintilimab treatment for non-small cell lung cancer with RET fusion and high PD-L1 expression. This study explores the biomarker selection for targeted therapy and combined immunotherapy in NSCLC patients.

    Keywords: Non-small cell lung cancer, RET fusion, High PD-L1 expression, Anlotinib, Sintilimab

    Received: 13 Jun 2024; Accepted: 15 Nov 2024.

    Copyright: © 2024 Bao, Zhang, Wang, Chen, Luo, Li, Su, Bao, Cao and Lin. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Hejing Bao, Department of Oncology, Guangzhou Medical University, Guangzhou, 510170, Guangdong Province, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.